$101.07
+0.68%Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Wall Street analysts project that RVTY stock may experience modest gains over the coming 12 months. The consensus 1-year price target stands at 108.88, with estimates ranging from a low of 95.00 to a high of 124.00.
The consensus 1-year price target stands at 108.88, with estimates ranging from a low of 95.00 to a high of 124.00.
Moderate upside. Analysts expect positive returns but with limited margin of safety. Consider entry timing.
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Declining expectations indicate headwindsโinvestigate whether temporary or structural issues.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
During the last 12 months, insiders have sold $1.02M worth of RVTY shares, with no buying activity reported.
0
0.00
80
7.42K
-7K
-$7K
0
0.00
9.5K
970.13K
-970K
-$970K
0
0.00
0
0.00
+0
+$0
0
0.00
500
44.51K
-45K
-$45K
No buying activity
Vohra Tajinder S
Officer: Please See Remarks
$602K
Victor Miriame
Officer: Please See Remarks
$181K
Singh Prahlad R.
Director, Officer: Please See Remarks
$129K
Mcmurry-Heath Michelle
Director
$58K
Michas Alexis P
Director
$45K
Strong bearish signal with $1.02M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
Continue your RVTY research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.